Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RET

HER-2/BRAF/KRAS and METПодробнее

Targeting HER2, BRAF, KRAS, METПодробнее

RET/MET/BRAF: initial treatment, acquired resistance, Q&A Joshua Sabari, MD Joshua Bauml, MDПодробнее

Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunitiesПодробнее

RET in Lung Cancer: The Next Big Target?Подробнее

Dr. Marks on the Role of TKIs in HER2-Positive Breast CancerПодробнее

Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - NoПодробнее

Targeting HER2, BRAF, KRAS, MET, TRKПодробнее

Dr. Leighl Discusses Binimetinib in KRAS-Mutated NSCLCПодробнее

Progress Made in Treating BRAF V600E+ Metastatic NSCLCПодробнее

The evolution of HER2 targeting in metastatic breast breast cancerПодробнее

Reducing Risk in Residual Breast CancerПодробнее

Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast CancerПодробнее

2021 West Oncology | Lung Cancer | Targeted TherapiesПодробнее

Immunotherapy Combination in HER2-Positive Breast CancerПодробнее

HER2 Targeted Therapy for Treatment of NSCLCПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее